The information from the RESTORE trial helped to clarify an important
question about whether or not Tysabri (natalizumab) can be used
intermittently. The results suggest that a planned interruption of
treatment results in a worsening of the MS. Clinical worsening occurred
in as little as 1 month, whereas MRI changes did not occur until after
the third month without natalizumab.
Click here to read more
